Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra
Download the release

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.
 

1.Details of the person discharging managerial responsibilities/person closely associated
a)NameMonika Lessl
2.Reason for the notification
a)Position/statusBoard member in Gubra
b)Initial notification/ AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGubra A/S
b)LEI254900T17RRFZONO6W53
4.1Details of the transaction(s):
a)Description of the financial instrument, type of instrument
 
Identification code
Shares
 
 ISIN DK0062266474
b)Nature of the transactionPurchase
c)Price(s) and volume(s)Price(s)Volume(s)
DKK 478306
d)Aggregated information
— Aggregated volume
— Price
Average price per share: DKK 478
Total number of shares: 306
Total price: DKK 146,268
e)Date of the transaction28 June 2024
f)Place of the transactionNASDAQ Copenhagen A/S

 

Contacts at Gubra
Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586
Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See www.gubra.dk for more information.

This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-06-28 12:05 CEST.

Attachments
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team